Literature DB >> 9888322

Photodynamic therapy with local photosensitizer delivery inhibits experimental intimal hyperplasia.

F Adili1, R G Statius van Eps, T J Flotte, G M LaMuraglia.   

Abstract

BACKGROUND: Photodynamic therapy (PDT), the light activation of photosensitizer dyes for the production of free radicals, effectively inhibits experimental intimal hyperplasia with systemic administration of the photosensitizer. The local application of the photosensitizer directly into a vascular lesion to avoid systemic side effects and tightly control dose administration has theoretical appeal. The aim of this study was to quantify serum and arterial tissue uptake after site-specific photosensitizer delivery and, following PDT, determine its effectiveness at inhibiting intimal hyperplasia. STUDY DESIGN/
MATERIALS AND METHODS: The rat common carotid artery was balloon-injured, pressurized at 400 mm Hg for 2 minutes with the photosensitizer dye benzoporphyrin-derivative (BPD), and irradiated with 690 nm laser light at a fluence of 100 J/cm2. Control animals were pressurized with saline only, or received no additional treatment than balloon-injury.
RESULTS: Pressurization with BPD resulted in complete penetration of the intima and media and was associated with relatively high tissue, but almost no detectable serum BPD concentrations. No skin photosensitization or other systemic side effects were observed with photosensitizer administration. After 9 days, PDT-treated arteries displayed a significantly lower number of smooth muscle cells in the arterial wall than balloon-injured (P < 0.001) or saline-pressurized arteries (P < 0.0002), and no intimal hyperplasia. At 21 days, IH after PDT was significantly reduced as compared with balloon-injured (P < 0.0004), or saline-pressurized arteries (P < 0.003) with no arterial dilatation.
CONCLUSIONS: Site-specific delivery of liposomal BPD followed by PDT represents a safe method to treat arteries, and may be effectively used in vivo to inhibit the development of intimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9888322     DOI: 10.1002/(sici)1096-9101(1998)23:5<263::aid-lsm6>3.0.co;2-v

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  6 in total

Review 1.  Photodynamic therapy.

Authors:  D C Shackley; C Whitehurst; N W Clarke; C Betts; J V Moore
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

2.  Long-term inhibition of intimal hyperplasia using vascular photodynamic therapy in balloon-injured carotid arteries.

Authors:  Takeshi Wakamatsu; Takashi Saito; Junichi Hayashi; Toshiaki Takeichi; Kiyoshi Kitamoto; Katsuo Aizawa
Journal:  Med Mol Morphol       Date:  2005-12       Impact factor: 2.309

3.  Mitochondrial release of apoptosis-inducing factor and cytochrome c during smooth muscle cell apoptosis.

Authors:  D J Granville; B A Cassidy; D O Ruehlmann; J C Choy; C Brenner; G Kroemer; C van Breemen; P Margaron; D W Hunt; B M McManus
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Photodynamic therapy of balloon-injured rat carotid arteries using indocyanine green.

Authors:  Jih-Shyong Lin; Chia-Jung Wang; Wen-Tyng Li
Journal:  Lasers Med Sci       Date:  2018-03-28       Impact factor: 3.161

5.  Chemiexcited Photodynamic Therapy Integrated in Polymeric Nanoparticles Capable of MRI Against Atherosclerosis.

Authors:  Dan Mu; Xin Wang; Huiting Wang; Xuan Sun; Qing Dai; Pin Lv; Renyuan Liu; Yu Qi; Jun Xie; Biao Xu; Bing Zhang
Journal:  Int J Nanomedicine       Date:  2022-05-20

6.  Intra-Arterial Drug and Light Delivery for Photodynamic Therapy Using Visudyne®: Implication for Atherosclerotic Plaque Treatment.

Authors:  Manish Jain; Matthieu Zellweger; Aurélien Frobert; Jérémy Valentin; Hubert van den Bergh; Georges Wagnières; Stéphane Cook; Marie-Noelle Giraud
Journal:  Front Physiol       Date:  2016-09-12       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.